The biotech has ambitions however to expand the use of the drug to other diseases that involve CD123, which include chronic myelomonocytic leukaemia (CMML), myelofibrosis and acute myeloid ...
A large segment of the CYP2C19 rapid metabolizer subgroup is nonresponder to the PPI treatment, only partial symptom relief in GERD, more frequent unsuccessful eradication therapy and lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback